{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:53:04Z","timestamp":1776966784723,"version":"3.51.4"},"reference-count":22,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BLCTT"],"DOI":"10.2147\/blctt.s516356","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:30:14Z","timestamp":1749123014000},"page":"11-20","source":"Crossref","is-referenced-by-count":2,"title":["An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Luciano","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarasa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aster","family":"Meche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chai Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cislo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-4676","authenticated-orcid":true,"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","unstructured":"SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Available from: https:\/\/seer.cancer.gov\/explorer\/. Accessed February 23, 2023."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.18185","volume":"198","author":"Costa","year":"2022","journal-title":"Br J Haematol"},{"key":"ref6","unstructured":"ABECMA\u00ae (idecabtagene vicleucel) [package insert]. Summit, NJ: Celgene Corporation; 2021."},{"key":"ref7","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2022."},{"key":"ref8","unstructured":"TECVAYLI\u2122 (teclistamab-cqyv) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2022."},{"key":"ref9","unstructured":"TALVEY\u2122 (talquetamab-tgvs) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2023."},{"key":"ref10","unstructured":"ELREXFIOTM (elranatamab-bcmm). Prescribing information. Pfizer, Inc. New York, NY, USA (2023)."},{"key":"ref11","unstructured":"ELREXFIOTM (elranatamab). Summary of product characteristics. Pfizer, Inc. New York, NY, USA (2024)."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","volume":"40","author":"Mol","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"Mol","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2023-0995","volume":"20","author":"Costa","year":"2024","journal-title":"Future Oncol"},{"key":"ref18","first-page":"1","volume":"45","author":"van","year":"2011","journal-title":"J Stat Softw"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/EDE.0000000000001381","volume":"32","author":"MacLehose","year":"2021","journal-title":"Epidemiology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Meth"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"}],"container-title":["Blood and Lymphatic Cancer: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/103619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/103619","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:30:18Z","timestamp":1749123018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/an-updated-indirect-comparison-of-elranatamab-versus-a-real-world-exte-peer-reviewed-fulltext-article-BLCTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2147\/blctt.s516356","relation":{},"ISSN":["1179-9889"],"issn-type":[{"value":"1179-9889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}